Former Senior Vice President, Chief Medical Officer · Mersana Therapeutics, Inc. (MRSN)

Arvin Yang

A named executive officer of Mersana Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,912,352

Salary $409,744Stock awards $292,898

FY2022: $1,540,957

3rd of 7 named executive officers at Mersana Therapeutics by FY2023 total.

7 named officers on file for Mersana Therapeutics, FY2023

Arvin Yang’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • MRSN’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Mersana Therapeutics’s whole pay program stands against its peers

  • Mersana Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MRSN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Arvin Yang’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Arvin Yang compensation by year

Mersana Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Mersana Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023
Salary$44,462$510,000$527,850$409,744
Bonus$0$0$0$0
Stock awards$942,760$0$177,931$292,898
Option awards$3,523,840$0$582,726$1,053,396
Non-equity incentive$0$201,960$245,450$0
Pension and deferred compensation$0$0$0$0
All other$0$157,000$7,000$156,314
Total$4,511,062$868,960$1,540,957$1,912,352

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mersana Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0001104659-24-052235, and prior-year filings.

How this page was built: the Mersana Therapeutics, Inc. filed document, accession 0001104659-24-052235. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$4.5M
$869K
$1.5M
$1.9M
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU28,333$166,031—
Option100,000—$25.48
Option103,594—$6.28

Per the Outstanding Equity Awards at Fiscal Year-End table in Mersana Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Mersana Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Anna ProtopapasFormer President and Chief Executive Officer$4,450,009
Martin HuberPresident and Chief Executive Officer$2,601,249
Arvin Yang · this pageFormer Senior Vice President, Chief Medical Officer$1,912,352
Brian DeSchuytnerSenior Vice President, Chief Operating Officer and Chief Financial Officer$1,738,215
Timothy LowingerSenior Vice President, Chief Science and Technology Officer$1,689,068
Alejandra CarvajalSenior Vice President, Chief Legal Officer$1,613,231
Mohan BalaSenior Vice President, Chief Development Officer$1,581,334

The full Mersana Therapeutics compensation record

free company brief

This page is one person within Mersana Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mersana Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mersana Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Arvin Yang's compensation dossier · One-time report. No refunds.